Related Experiment Video
Updated: Aug 29, 2025

Live Cell Imaging to Assess the Dynamics of Metaphase Timing and Cell Fate Following Mitotic Spindle Perturbations
Published on: September 20, 2019
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with
Isabel Soria-Bretones1,2,3, Kelsie L Thu1,4,5, Jennifer Silvester1
1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Abstract:
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) are standard first-line treatments for metastatic ER+ breast cancer. However, acquired resistance to CDK4/6i invariably develops, and the molecular phenotypes and exploitable vulnerabilities associated with resistance are not yet fully characterized. We developed a panel of CDK4/6i-resistant breast cancer cell lines and patient-derived organoids and demonstrate that a subset of resistant models accumulates mitotic segregation errors and micronuclei, displaying increased sensitivity to inhibitors of mitotic checkpoint regulators TTK and Aurora kinase A/B. RB1 loss, a well-recognized mechanism of CDK4/6i resistance, causes such mitotic defects and confers enhanced sensitivity to TTK inhibition. In these models, inhibition of TTK with CFI-402257 induces premature chromosome segregation, leading to excessive mitotic segregation errors, DNA damage, and cell death. These findings nominate the TTK inhibitor CFI-402257 as a therapeutic strategy for a defined subset of ER+ breast cancer patients who develop resistance to CDK4/6i.
Insights
A subset of estrogen receptor-positive (ER+) metastatic breast cancer resistant to CDK4/6 inhibitors develops defects in cell division. These defects make the cancer vulnerable to TTK inhibitors like CFI-402257.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) are a standard treatment for ER+ metastatic breast cancer.
- Acquired resistance to CDK4/6i is a significant clinical challenge, necessitating the characterization of resistance mechanisms and vulnerabilities.
Purpose of the Study:
- To investigate the molecular phenotypes and exploitable vulnerabilities in CDK4/6i-resistant breast cancer.
- To identify potential therapeutic strategies for patients with acquired resistance to CDK4/6i.
Main Methods:
- Development of CDK4/6i-resistant breast cancer cell lines and patient-derived organoids.
- Analysis of mitotic fidelity and chromosomal segregation in resistant models.
- Evaluation of sensitivity to inhibitors of mitotic checkpoint regulators, specifically TTK and Aurora kinase A/B.
- Assessment of the efficacy of the TTK inhibitor CFI-402257 in resistant models.
Main Results:
- A subset of CDK4/6i-resistant models exhibited mitotic segregation errors and micronuclei formation.
- Loss of RB1, a known resistance mechanism, was associated with these mitotic defects.
- These defects conferred enhanced sensitivity to TTK inhibition.
- Treatment with CFI-402257 induced premature chromosome segregation, DNA damage, and cell death in sensitive models.
Conclusions:
- Mitotic defects and sensitivity to TTK inhibition represent a vulnerability in a subset of CDK4/6i-resistant ER+ breast cancers.
- The TTK inhibitor CFI-402257 shows therapeutic potential for this specific patient population.
- Targeting mitotic checkpoint regulators offers a promising strategy to overcome CDK4/6i resistance in breast cancer.
More Related Videos
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
DNA Damage can Stall the Cell Cycle
The Mitotic Spindle
The bipolar configuration of the mitotic spindle facilitates chromosomal segregation, preparing the cell for division. One mechanism that ensures...